Background: Dengue shock syndrome (DSS) represents one of the most severe manifestations of dengue virus infection. The objective of the present study was to analyze the clinical and laboratory characteristics, risk factors and outcome of DSS in children. Methods: Patients <15 years old admitted with DSS during the 2012 and 2013 outbreak of serotype 2 of dengue virus in Paraguay were included. Demographic, clinical and laboratory data of patients with/without DSS were analyzed. Results: Of 471 children hospitalized with dengue, 354 patients (75%) presented with shock at admission or developed later. The mean age of patients with DSS was 10.2 ± 4 years (no difference with patients without shock), without gender preference. Rash (50% vs. 56%), myalgias (45% vs. 40%), vomiting (66% vs. 68%) and bleeding manifestations (24% vs. 21.2%) were similar for 2 groups. Similarly, there was no difference in the frequency of DSS between primary versus secondary infection cases (76.2% vs. 71.6%, P = 0.3). Age group >5 years [odds ratio (OR) 1.6, 95% confidence interval (CI): 1-2.8, P < 0.05), presence of abdominal pain (OR 2.5, 95% CI: 1.3-4.9, P = 0.006), an activated partial thromboplastin time prolonged (OR 4; 95% CI: 1.6-10, P < 0.001) and low fibrinogen level (OR 2.5; 95% CI: 1-5.9, P = 0.02) were found significantly associated with DSS. About 12% of patients required intensive care unit admission, and 2 patients died (lethality 0.35%). Conclusions: This study validated most of the clinical variables present in the current WHO guidelines as markers of severe disease and add additional variables that can help to predict the risk of progression to shock.
D
engue fever is a viral infection caused by a flavivirus (the dengue virus, DENV) with 4 different antigenically distinct serotypes (DENV1-4). 1 Currently, dengue is the most common arboviral disease globally. 2 Dengue is endemic in more than 100 countries worldwide, with an estimated 2.5 billion people living in areas at risk, mainly in the countries of south and Southeast Asia, the Caribbean, Central and South America. 3 Approximately 120 million people travel to these regions each year. Thus, the number of dengue cases has increased significantly in recent years among travelers returning from trips to endemic countries. 4 Among the different clinical presentations of dengue, dengue shock syndrome (DSS) is the most severe form and affects particularly children and young adults. [4] [5] [6] Fatal cases of dengue infection occur mostly in patients with DSS. Without proper treatment, the mortality of DSS is reportedly 50 times higher than that in dengue patients without DSS, 7 and the fatality rates for DSS may exceed 20%. 7, 8 In patients with DSS, early appropriate treatment can reduce mortality. 3, 6, 7, 8 Therefore, tools that permit identification of which patient will develop shock or other severe manifestations of dengue can reduce the health care burden of dengue infection in endemic countries and decrease the mortality. Therefore, determination of risk factors of DSS is crucial for the early detection and proper management of shock.
Although several studies have analyzed this subject, the associations for some factors have not been observed consistently across studies. [8] [9] [10] [11] [12] [13] [14] [15] [16] An important outbreak of dengue serotype 2 occurred in Paraguay-country sited in the south of America among Brazil, Argentina and Bolivia-during 2011 to 2013 that resulted in more than 500 children hospitalized in the Tropical Medicine Institute of Asuncion, the capital of the country. 17 This allowed us to reassess the risk factors and outcomes of DSS in the pediatric population.
MATERIALS AND METHODS

Population and Study Design
Children admitted to the Institute of Tropical Medicine (ITM) with the diagnosis of dengue fever during the 2011 to 2013 outbreak of dengue serotype 2 in Paraguay were included in this study. ITM is a tertiary care teaching institution and is the main referral center for infectious and tropical diseases in Paraguay. This study was approved by the institution research ethics board.
The criteria for hospitalization of dengue cases were previously set in national guidelines for management of dengue fever, 18 a local adaptation of the 2009 WHO guidelines for diagnosis, treatment, prevention and control of dengue. 4 In short, this guideline distinguishes between severe and nonsevere dengue. Severe dengue is defined by the occurrence of plasma leakage and/or fluid accumulation leading to shock (DSS) or respiratory distress; and/or severe bleeding; and/or severe organ impairment. The nonsevere dengue group is divided into patients with and without warning signs. Cases of dengue with warning signs included the presence of factors associated with greater morbidity and mortality such as abdominal pain, persistent vomiting, intolerance to oral, clinical accumulation of fluid, bleeding of mucous membranes, lethargy/restlessness, precordial pain, hepatomegaly or laboratory data, such as thrombocytopenia less than 100,000/mm 3 , hemoconcentration, documented by the hematocrit increased up to 20% or more. Only cases of dengue with warning signs or severe criteria were hospitalized.
Several laboratory methods were employed for the confirmation of dengue including qualitative detection of IgG and IgM antibodies specific to dengue (anti-DEN IgG and IgM; SD Dengue IgM and IgG Capture enzyme-linked immunosorbent assay, Standard Diagnostics INC, South Korea), demonstration of nonspecific protein of DENV (dengue NS1) by immunochromatography (Bioeasy, Standard Diagnostics INC, Republic of Korea) and detection of DENV genomic sequences by polymerase chain reaction (PCR). A laboratory-confirmed case was defined by the presence of positive dengue NS1 test or by the detection of DENV RNA in plasma. Patients in whom the dengue-specific IgM was already high at the onset of shock were also considered as confirmed dengue, provided that the overall clinical picture was consistent with DSS, and no alternative diagnosis was established. In patients whose PCR, NS1 antigen test, anti-DEN IgM/IgG-negative testing were negative on the sample obtained at the time of admission, a second serum sample was obtained (convalescent sera) for determination besides anti-DEN IgM, anti-DEN IgG neutralization titers. A ≥4-fold rise in DENV HAI IgG titers between 2 different points in time was also confirmatory of dengue. Cases with a clear epidemiological link were also included (classical clinical pictures plus one or more cases of dengue in people living in the same household).
Patients who exhibited at admission PCR or NS1 antigen capture test positive with anti-DEN IgM positive and IgG negative were considered to have a primary Dengue infection. In the absence of PCR or NS1 Ag test positive, the new appearance of anti-DEN IgM with anti-DEN IgG negative was also considered to be a primary infection. Patients with PCR or NS1 antigen test positive at admission with IgG positive (with or without anti-DEN IgM positive) were considered to have a secondary dengue infection.
The population of hospitalized patients was divided into 2 groups, depending on the presence of shock. Patients were considered to have shock if the pulse pressure was 20 mm Hg or lower, or signs of poor capillary perfusion (cold extremities, delayed capillary refill or rapid pulse rate) were present. Patients with hematologic disorders, congenital heart diseases (known or suspected), congenital or acquired immunodeficiency, cancer and chronic lung or renal diseases were excluded.
All subjects were admitted to the hospital and monitored until 24 hours after defervescence. Fluid management was carried out following the recommendations of the 2009 WHO Dengue Guideline, 4 which is characterized by early and titrated intravenous fluid therapy. Our management of shock has been previously published 18 and included a bolus of 20 mL/kg of isotonic crystalloid solution (such as 0.9% normal saline or lactated Ringer solution) infused as rapidly as possible. The 20 mL/kg fluid boluses were repeated until blood pressure, tissue perfusion and oxygen delivery were adequate, or signs of fluid overload (rales, gallop rhythm, enlarged liver) develop. Once effective circulating volume has been restored, the rate of infusion of saline solution was decreased and further followed by the maintenance volume of hydration. 4 
Data Collection
Signs and symptoms, findings on physical examination and routine laboratory test data were obtained at admission and during the hospital stay with a standardized case report form. Laboratory parameters, including hemoglobin, total and differential leukocyte count, platelet count, serum C-reactive protein, blood urea, serum creatinine, prothrombin time (PT), activated partial thromboplastin time (APTT) with international normalized ratio, electrolytes, blood pH, serum bicarbonate, arterial oxygen (PaO 2 ) and carbon dioxide content (PaCO 2 ), were obtained. A complete blood count was done daily. Blood chemistry, radiographic imaging and abdominal ultrasound were done to monitor the course of the disease, especially during defervescence.
Statistical Analysis
Continuous variables were expressed as mean ± SD and categorical variables as numbers and percentages. Analysis of factor-specific relationships with DSS was performed. Platelet count, besides median count, was dichotomized at 100,000/mm 3 and 50,000/mm 3 , as these are the levels at which complications occur more frequently. Univariate analyses were performed to investigate the association of the relevant independent variables with the outcomes; χ 2 tests, Fisher exact tests and odds ratios (OR) were calculated where appropriate. Factors associated with shock on univariate analysis with a P value <0.10 were further assessed by multivariate logistic regression with correction for age and gender, with results given as OR and 95% confidence intervals (CIs). A P value <0.05 was accepted as statistically significant for all analyses. All analyses were performed with the statistical software R, version 2.15.0.
RESULTS
In the study period, 560 children less than 15 years of age were admitted to the ITM with the clinical diagnosis of dengue viral infection. Only patients with laboratory confirmation of the diagnosis or with an unquestionable epidemiological link were included in the analysis.
The diagnosis of dengue was confirmed by a positive PCR or NS1 antigen capture test in 242 patients (139 of this group showed also the presence of anti-DEN IgM and 74 of both anti-DEN IgM and IgG antibodies), by new appearance of anti-DEN IgM in 170 children (125 of this group showed also anti-DEN IgG). In addition, in 23 patients, the diagnosis was based in ≥4-fold rise in DENV HAI IgG titers between 2 points in time, and in 36 children, dengue diagnosis was made by epidemiological link. In summary, 471 patients were finally included in the analysis.
Relevant demographic, clinical and laboratory characteristics of the study population are shown in Table 1 . Briefly, the mean age of dengue patients admitted was 10 ± 4 years, and the main age group affected has been children beyond 5 years of age (84%), with a similar gender distribution. Symptoms and clinical signs at admission were those commonly observed in a series of cases of dengue. Three hundred and fifty-four patients (75%) were admitted with shock (cases of DSS) or developed it during hospitalization. The others were cases of dengue with warning signs or severe dengue without shock (n = 117, 25%). In 310 patients (87, 6%), the shock was during the compensatory stage, whereas 44 (12%) of the remainder exhibited hypotension. Tables 2 and 3 show the main characteristics of patients with shock in comparison to those patients who required hospitalization but did not develop it. The mean age of patients with shock was no different from patients who did not develop shock during the hospitalization (10, 2 ± 4 years vs. 9, 5 ± 4.5 years). However, in age group comparisons, patients >5 years of age were more likely to develop shock compared with other groups (77% vs. 62.5% in the group from 2 to 5 years and 62% in children <24 months, P < 0.05; OR 1, 95% CI: 1-2.8). There were no significant differences based on gender (male/female ratio 1:1) and location of the residence between both groups. Further, neither malnutrition, obesity nor overweight was associated with DSS (Table 2) .
There were no differences in the frequency of rash (49.4% vs. 58.9%), myalgias/arthralgias (49.4% vs. 42.7%), headache (65.2% vs. 60.6%), vomiting (68.6% vs. 65.8%) and bleeding manifestations (26% vs. 26%) among those who developed shock compared with those who never presented it. When only severe cases of bleeding were analyzed, this finding was significantly more frequent in patients with shock (9% vs. 2.5%; OR 3.7, 95% CI: 1.1-12, P = 0.02). Abdominal pain was the other clinical sign found with higher incidence in patients with shock (78.5% vs. 69%; OR 1.6, 95% CI: 1-2.6, P < 0.05; Table 3 ).
Patients with shock demonstrated an almost similar degree of hemoconcentration compared with patients without shock, both at admission (39.5% ± 5.8% vs. 39.1% ± 5.7%) and during the hospitalization (41.5% ± 6.8% vs. 40.5% ± 6.8%). When a hematocrit cutoff value >40% was explored as risk factor of shock, it was not significantly associated with the development of shock (OR 1.4, 95% CI: 0.9-2.1, P = 0.1). When signs of plasma leakage was analyzed, both groups exhibited the same frequency. However, the presence of effusion in more than 1 cavity (eg, pleural effusion plus ascites or thickened gallbladder) compared with its absence or its presence in only 1 cavity was significantly related to major fluid requirements, indicating that it is a marker of severity ( . When a platelet count cutoff value of <100,000/mm 3 was explored as risk factors of shock, it was found that children who did not develop shock exhibit in similar percentage; this level of thrombocytopenia compared with patients who eventually developed it (47% vs. 49%, respectively; OR 1.7, 95% CI: 0.7-1.8, P = 0.59; Table 3 ). The results were similar when the comparison included patients only with platelets counts <50,000/mm 3 (28% vs. 25.6%, respectively; OR 1, 95% CI: 0.6-1.8, P = 0.6).
Among the other laboratory data, only the presence of a prolonged activated partial thromboplastin time and low fibrinogen level at admission was associated with DSS. None of the other laboratory variables in patients were different when they were compared between patients who developed shock versus patients who did not; hence they were not considered to be specific risk factors for the development of shock (Table 5 ).
In 388 patients (82.5%), we could determine whether the cases were primary (n = 141) or secondary dengue infection (n = 248). In 82 patients (17.4%), the distinction could not be made. Patients with primary infection developed shock (71.6%) in the same proportion as those with secondary dengue (75%, P = 0.2). When the comparisons were done for the different age groups, the results were similar: 70.5% versus 67% in the <2 years of age group (P = 0.8), 65% versus 76% in the 2-5 years old group (P = 0.8) and 73% versus 84% in the group of children with >5 years of age.
Fifty-seven patients (12%) developed prolonged shock and needed intensive care unit admission. Only 6 children (1.3%) were given blood products (packed red blood cells in 2, platelet concentrates in 2 and both in 1 patient). The overall case fatality rate in the study population was 1.3% (6/471 patients).
DISCUSSION
One of the most important challenges faced by the staff physicians who care for patients with dengue is the early identification of hospitalized patients at higher risk for developing shock. A previous multicenter study involving cases of dengue from different countries including Paraguay analyzed the association of dengue serotypes with clinical manifestations, however, the study did not include inpatients. 19 This study done in hospitalized patients with dengue focused in particular on the correlation of clinical symptoms/signs and laboratory data with the development of DSS.
Although the clinical presentations of dengue patients at admission were similar to previous descriptions of dengue with warning signs, we found differences regarding symptoms/signs that were reported to be associated with DSS. Series from Latin America and Southeast Asia showed higher prevalence of severe dengue in women, including a recently published meta-analysis, which clearly demonstrated the association of female gender with the risk of DSS. 12, 20, 21 However, we did not observe any differences in gender when correlated with the development of shock. This same finding was reported recently with dengue in El Salvador. 22 Different reports have indicated that young children have an increased risk of DSS 15, 16, 23, 24 probably because of an increased microvascular fragility in younger children. 25 In the present study, however, shock was not more common in the children under 2 years of age. Among the different pediatric age groups, DSS was more frequent in children >5 years of age. Other authors have also reported this finding. 13, 14, 26 Because the group of children older than 5 years of age in our study was significantly larger (n = 394, 84%) than those younger than 5 (n = 77, 16%), a bias of the sample distribution since the enrollment cannot be excluded. Several reports suggest that normal nutrition is a risk factor of DSS, while malnutrition could be a protective factor, probably related to suppressed immune activation in malnourished children. [12] [13] [14] 23 In our series of patients, however, we did not find any differences in the nutritional status among patients who develop shock compared with those with dengue without shock.
Various symptoms and signs were included as warning signs in the last WHO dengue guideline. 4 Although they have been shown to be very useful for early intervention (mainly fluid therapy), in the present series only few signs of dengue severity were identified to be associated with the development of shock, such as abdominal pain as well as effusion in more than 1 cavity. 27 These findings are manifestations of the severe increase in capillary leakage, the main pathological cause of development of shock [27] [28] [29] and are consistent with findings in the pediatric population in Puerto Rico, Cuba and Colombia. 26, 30, 31 Although other series identified bleeding manifestations as risk factors of shock, 16, 26, 32, 33 in our study only the presence of severe bleeding was associated with shock. It has been shown that the severity of bleeding is closely related, among others factors, with increased microvascular fragility and poor capillary perfusion. 34, 35 Thus, severe bleeding during the course of the disease should alarm clinicians that the dengue patients are at risk of shock.
In our study, the presence of hemoconcentration in patients hospitalized with warning signs was a frequent finding in the age group of children >5 years of age but was only found in 17% in children <2 years of age. Compared with studies from Southeast Asia, where hemoconcentration was found in 90% of patients with DSS, [36] [37] [38] our patients demonstrated a much smaller degree of hemoconcentration (10%-20%) than expected by the current definitions. The mean of hematocrit was similar when patients with shock were compared with patients without shock, and hemoconcentration ≥20% was observed only in 55% of the patients with shock. However, a similar percentage was observed also in dengue patients without shock (50.5%). Hemoconcentration below the WHO threshold of 20% has been noted previously in DSS patients. 22, 39 Four hundred and seven hospitalized patients (86%) exhibited thrombocytopenia, which was <100,000/mm 3 [1 of the 4 components of the definition of dengue hemorrhagic fever (DHF)] in 351 of them (74.5%). This figure shows the severity of hospitalized cases of dengue in our institution, where only patients with warning signs or with shock are hospitalized. It was demonstrated that the severity of the thrombocytopenia is correlated with plasma viral load, which has been shown to correlate also with the extent of plasma leakage. 35 Contrary to other studies, however, where severe thrombocytopenia was associated with higher risk of shock, 4, 8, 12, 40 in our study both the mean platelet count and a low platelet count (<20,000/mm 3 ) were found in similar proportion in patients with and without shock.
A reduction in fibrinogen concentration and an increase in the PT and APTT were consistent coagulation abnormalities detected between 16% and 25% of the patients. Other studies have demonstrated the temporal association of the APTT and fibrinogen changes with the period of maximal vascular leakage. The decrease in the fibrinogen concentration could be explained by the increase in transcapillary filtration in a similar manner to that of albumin. 29 Changes in the capillary structure can also explain the prolongation of the APTT. Damage of the glycocalix of endothelial cells can result in the release of heparan sulfate into the circulation, which would act as an anticoagulant similar to heparin. Reduction of fibrinogen level and prolongation of APTT showed a positive association with DSS. These observations are not surprising, because both coagulation abnormalities are strongly associated with vascular leakage both temporally and in terms of severity. 41, 42 Prospective studies in Thailand and other countries from the Southeast Asia, [43] [44] [45] as well as studies of sequential epidemics of dengue in Cuba, 46 have shown the association of secondary infection with more severe disease, probably related to the role of antibodydependent enhancement in DSS pathogenesis. 1 In our study, however, cases of DSS were observed in similar percentage in patients with primary or secondary infection. It is important to notice that the majority of patients were hospitalized during the outbreak of infection of DEN 2 serotype. The genotype of DEN 2 virus has been associated with increased disease severity, whether in the context of secondary infection or otherwise. 47, 48 Preliminary observations indicate that the Dengue 2 virus responsible for the last outbreak that occurred in Paraguay are phylogenetically associated with the strains originated in Southeast Asia (Cinthia Vazquez, BS, personal communication, December 1, 2015). The major success of the Southeast Asian dengue 2 strain is probably because of more efficient replication in human target cells as well increased transmission by vector mosquitoes. 47 The mortality rate of the present series was low (1.2%), considering that the denominator has included only severe cases of dengue. Same aspect of the management of the cases are worthy of mention. The use of blood products (packed red blood cells or platelet concentrates) was infrequent, even in patients with a very low platelet count. Most patients recovered well with the standard titrated intravenous fluid therapy, and only a minimal proportion of patients required inotropic support.
Our study has a number of limitations because of its retrospective design and the fact that data were collected from a referral center. Thus, the results may not be applicable to community health care settings. In addition, it should be considered that the vast majority of patients were cases of infection by the dengue serotype 2. The epidemiology of dengue is different in different geographical areas and depends upon circulating serotypes, and thus it can vary from year to year. For this reason, the variables found to be associated with the development of shock may not be applicable to other areas.
Despite the known limitations of this study, our findings suggest specific risk factors that may predict the development of shock. Prospective studies to confirm our findings are needed.
